CGON CG Oncology Inc.
Price Chart
Executive Summary
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, but the headline is the BLA completion timeline for cretostimogene in BCG-unresponsive NMIBC now guided to Q4 2026, with Phase 3 PIVOT-006 topline data expected in H1 2026. The company raised $391.4M via ATM in Q1, boosting cash to $1.1B, sufficient through 2029, and reported first commercial revenue of $1.07M. The stock will move on the BLA timeline clarity and upcoming PIVOT-006 data readout.
Actionable Insight
The BLA completion guidance to Q4 2026 and upcoming PIVOT-006 data in H1 2026 are the key catalysts. The CORE-008 Cohort CX data at AUA on May 16 could provide early read on combination therapy. The $1.1B cash runway through 2029 removes near-term financing risk. Monitor the PIVOT-006 topline for potential approval expansion into intermediate-risk NMIBC.
Key Facts
- BLA completion for cretostimogene in HR BCG-unresponsive NMIBC guided to Q4 2026 (previously no specific timeline)
- Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC expected H1 2026
- First results from CORE-008 Cohort CX (cretostimogene + gemcitabine) to be presented at AUA May 16, 2026
- Net loss of $60.2M ($0.71/share) vs $34.5M ($0.45/share) in Q1 2025
- Cash, cash equivalents and marketable securities of $1.1B, up from $742.2M at Dec 2025
- Raised ~$391.4M via ATM facility in Q1 2026 from 6.94M shares
- First commercial and development revenue of $1.07M reported (vs $0 in Q1 2025)
- R&D expenses increased to $43.7M from $27.5M; G&A expenses increased to $20.8M from $14.8M
Financial Impact
Net loss widened to $60.2M from $34.5M; cash position strengthened to $1.1B from $742.2M; first commercial revenue of $1.07M reported
Risk Factors
- PIVOT-006 topline data may miss efficacy endpoints, delaying label expansion
- BLA submission could face CMC delays beyond Q4 2026 guidance
- Widening net loss trajectory with no near-term profitability expected
- Competitive landscape in NMIBC (Keytruda, other oncolytic viruses)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291055 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
8-K
| $61.89 $59.23 | ▼ −4.30% | ▼ −5.38% | $56.67 (−8.43%) |
|
May 15, 2026
25d ago
|
Press Release
| $66.93 $64.25 | ▼ −4.00% | ▼ −4.97% | $56.67 (−15.33%) |
|
May 8, 2026
4w ago
|
8-K
| $69.62 $69.54 | ▼ −0.12% | ▼ −1.59% | $56.67 (−18.60%) |
|
May 8, 2026
4w ago
|
Press Release
| $69.62 $69.54 | ▼ −0.12% | ▼ −1.59% | $56.67 (−18.60%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $66.82 $67.70 | ▲ +1.32% | ▲ +0.92% | $56.67 (−15.19%) |
|
Apr 17, 2026
7w ago
|
144
| $70.40 $66.82 | ▼ −5.09% | ▼ −6.00% | $56.67 (−19.50%) |
|
Apr 13, 2026
8w ago
|
8-K
| $67.70 $70.40 | ▲ +3.99% | ▲ +0.69% | $56.67 (−16.29%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $57.76 $61.29 | ▲ +6.11% | ▲ +7.32% | $56.67 (−1.89%) |
|
Feb 27, 2026
14w ago
|
Press Release
| $58.80 $61.88 | ▲ +5.24% | ▲ +7.22% | $56.67 (−3.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access